Used in targeted cancer therapies, particularly for B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Binds specifically to CD22, a receptor found on the surface of B-cells, enabling precise delivery of cytotoxic agents or facilitating immune-mediated destruction of malignant cells. Employed as a targeting component in antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. Also utilized in diagnostic imaging and flow cytometry to detect and monitor B-cell populations in clinical samples. Shows potential in overcoming resistance to other antibody-based treatments by modulating B-cell receptor signaling pathways.